Master Protocol For Metastatic Breast Cancer Needs To Adapt To Rational Combinations
This article was originally published in Pharmaceutical Approvals Monthly
Beyond saving money and creating efficiencies, stakeholders want a master trial to foster true innovation in metastatic breast cancer treatment. Various ways to deal with dosing and other challenges in testing rational combinations of different interventions were discussed at recent workshop.
You may also be interested in...
Basket trials are building a path for tissue-agnostic drug development in oncology, and plans are proceeding for more master protocols in pediatric cancers, acute myeloid leukemia and pancreatic cancer.
Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.
In a final guidance on co-development of two or more investigational new drugs for use in combination, FDA lays out general principles for IND and marketing application submissions, a topic on which the agency essentially punted in a December 2010 draft document.